美国重症医学会FCCM药师学术活动基准
该研究通过Scopus和PubMed数据库回顾性分析2021年1月美国重症医学会认定的152名FCCM药师,最终纳入138名(91%)可评估者。其中位首次发表年份为2007年,中位发表数为20篇(IQR 9-43),从首次发表至FCCM授予期间中位发表10篇(IQR 5-19),中位被引244次(IQR 99-661),h指数中位8(IQR 5-13)。研究未设对照或干预,旨在为申请FCCM的药师提供学术活动基准。
要点
- FCCM药师中位总发表数为20篇(IQR 9-43),从首次发表至FCCM授予期间中位发表10篇(IQR 5-19)。
- FCCM药师中位h指数为8(IQR 5-13),中位被引244次(IQR 99-661)。
- 大多数FCCM药师在学术医学中心工作(n=116,84%),45%位于美国南部地区。
- 排除标准包括MCCM称号(n=7)、两个数据库均无数据(n=4)和无有效药师执照(n=3)。
- 研究未设对照或干预,仅提供描述性基准,不能作为申请FCCM的强制阈值。
适用人群与场景
- 2021年1月由美国重症医学会认定的FCCM药师,排除MCCM称号者、两个在线引文数据库均无数据者及无有效药师执照者。
- 最终纳入138名可评估的FCCM药师;多数在学术医学中心(n=116,84%)和美国南部地区(n=62,45%)工作。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型为回顾性数据库分析,样本量138名FCCM药师,无中心数描述,无干预对照。
- 主要终点:中位总发表数20篇(IQR 9-43),从首次发表至FCCM授予期间中位发表10篇(IQR 5-19)。
- 关键次要终点:中位被引244次(IQR 99-661),h指数中位8(IQR 5-13);学术活动形式以原创研究(n=3,173;71%)和综述(n=795;18%)为主。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型为回顾性数据库分析;原文未给出证据等级或推荐强度。
- 局限:仅纳入FCCM药师,无对照,排除MCCM称号者、无数据库数据者及无有效执照者,可能限制代表性。
对床旁实践的改变
- 该基准可供药师在申请FCCM前参考,用于评估自身学术活动(如总发表数、h指数)是否符合FCCM群体中位水平,但不作为强制阈值。
- 不适用于非FCCM药师或非药师群体;原文未提及对急诊/ICU临床实践的改变。
- 常见陷阱:将中位数值误读为申请FCCM的硬性门槛;原文未提供预测或验证数据。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Quantify scholarly activity by pharmacists who are Fellows within the American College of Critical Care Medicine and to develop a potential publication benchmark for fellowship application.
DESIGN: Review of the Scopus and PubMed online citation databases.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Pharmacists designated Fellow of Critical Care Medicine (FCCM) were identified in January 2021 by the Society of Critical Care Medicine. Pharmacists designated Master of Critical Care Medicine (MCCM), without an active license, or were not identified in either online citation database were excluded. Practice setting characteristics were obtained from the American Hospital Association including country, state, geographic region, number of staffed beds, and hospital designation. Two online citation databases (Scopus and PubMed) were queried in February 2021, and year of first publication, total publications, citations, and Hirsch index were recorded. Of the 152 pharmacists designated FCCM, 138 (91%) were evaluable. Reasons for exclusion included MCCM designation (n = 7; 5%), lack of data in either online citation database (n = 4; 3%), and no active pharmacist license (n = 3; 2%). Most pharmacists were practicing in the Southern geographic region of the United States (n = 62; 45%) and at an academic medical center (n = 116; 84%). The median year of FCCM convocation was 2016 (2012-2019) and of the first publication was 2007 (2002-2011). After removing duplicates, 4,488 unique publications were identified. The median number of publications per individual pharmacist was 20 (9-43) with 10 (5-19) between the year of their first publication and FCCM convocation. Most scholarly activity was in the form of original research (n = 3,173; 71%) or reviews (n = 795; 18%). Individual pharmacists have 244 (99-661) citations and an h-index of 8 (5-13).
CONCLUSIONS: Pharmacists designated FCCM have maintained a high level of scholarly activity. Pharmacists pursuing fellowship may use these data as a benchmark for fulfilling aspects of the core area of scholarly activities related to critical care medicine prior to application.
参考来源
- Sherman KM, Gagnon DJ. Benchmarking Scholarly Activity by Pharmacists Who Are Fellows Within the American College of Critical Care Medicine. Crit Care Explor. 2021. PMID: 34514422. doi:10.1097/CCE.0000000000000520
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。